- Joined
- Aug 4, 2020
- Messages
- 1,967
- Reaction score
- 3,351
LOL. We are constantly learning new information. There clearly are risks that go beyond 10 years and trial patients aren't community patients. "No differences" eh? Your 'outcome' of low risk patients having few differences in recurrence (local failures) outcome proves the obvious we already knew. What we didn't know was but f'd around and found out was: ultra short course may be acceptable but as noted, may have consequences with regards to side effects. Maybe we already knew that was coming from our old skool APBI trial.Man comprehension is difficult out there in MO!
Anyway - no - the way breast cancer studies work haven't changed since the 70s. Not one study has shown a difference in the 10 year update. I don't know how else to keep saying this.
Anyway:
I don't care for the personal attack(s) you're waging and find your holier-than-thou attitude pretty unpleasant. I'll say it again: I suggest we move on.